| OUTLOOK THERAPEUTICS |
| USA |
| Gesundheit |
| US69012T3059 / A4046T |
| 41O (Frankfurt) / OTLK (NASDAQ) |
| FRA:41O, ETR:41O, 41O:GR, NASDAQ:OTLK |
| - |
| https://outlooktherapeuti.. |
|
Outlook Therapeutics Inc. is a late clinical-stage biopharmaceutical company specializing in ophthalmology. The company is focused on developing and commercializing ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab designed for the treatmen..
>Volltext.. |
| 230.57 Mio. EUR |
| 247.46 Mio. EUR |
| - |
| - |
| - |
| - |
| 23.72 Mio. EUR |
| 6.76 Mio. EUR |
| - |
| 0.2 |
| - |
| - |
| - |
| - |
| - |
| OUTLOOK THERAPEUTICS, OUTLOOK THERAPEUTIC |
| 19.06.26 |
|